S.Africa in $208 mln AIDS drug venture with Swiss Lonza

February 10, 2012

South Africa on Friday unveiled plans for a 1.6 billion rand ($208 million, 157 million euro) pharmaceutical plant, in a joint venture with Swiss biochemicals group Lonza to produce anti-AIDS drugs.

The plant will produce the key ingredients needed to make the anti-retroviral drugs that have turned AIDS into a , rather than a in a nation where 5.6 million people have HIV.

"This joint venture, named Ketlaphela, will establish the first pharmaceutical plant to manufacture for anti-retroviral medicines in South Africa," Science Minister Naledi Pandor told journalists.

South Africa will invest 1.1 billion rands, while Lonza will put 500 million rands into the plant, whose name means "I will survive" in Sotho, she said.

"Lonza's high Swiss standards plus their superb track record of establishing and maintaining successful commercial operations in developing countries, make them a valuable and desirable partner," Pandor said.

The new plant will help stabilise the price of drugs used to fight AIDS, as South Africa currently imports the main ingredients needed.

The plant will create about 2,600 jobs once it's running in 2016, he added. About 3,800 people will be employed for its construction.

South Africa has the world's largest programme, serving 1.3 million people.

The treatment programme has already made gains in combating the epidemic, but the numbers of people needing drugs will keep growing as more and more people begin a lifetime on the medicines.

Explore further: South Africa unveils plan to halve HIV infections

Related Stories

South Africa unveils plan to halve HIV infections

December 1, 2011
President Jacob Zuma on Thursday unveiled a plan to halve the number of HIV infections over the next five years, cementing South Africa's turnaround from years of deadly denialism.

Recommended for you

HIV-1 genetic diversity is higher in vaginal tract than in blood during early infection

January 18, 2018
A first-of-its-kind study has found that the genetic diversity of human immunodeficiency virus type 1 (HIV-1) is higher in the vaginal tract than in the blood stream during early infection. This finding, published in PLOS ...

War in Ukraine has escalated HIV spread in the country: study

January 15, 2018
Conflict in Ukraine has increased the risk of HIV outbreaks throughout the country as displaced HIV-infected people move from war-affected regions to areas with higher risk of transmission, according to analysis by scientists.

Researchers offer new model for uncovering true HIV mortality rates in Zambia

January 12, 2018
A new study that seeks to better ascertain HIV mortality rates in Zambia could provide a model for improved national and regional surveillance approaches, and ultimately, more effective HIV treatment strategies.

New drug capsule may allow weekly HIV treatment

January 9, 2018
Researchers at MIT and Brigham and Women's Hospital have developed a capsule that can deliver a week's worth of HIV drugs in a single dose. This advance could make it much easier for patients to adhere to the strict schedule ...

New long-acting, less-toxic HIV drug suppresses virus in humanized mice

January 8, 2018
A team of Yale researchers tested a new chemical compound that suppresses HIV, protects immune cells, and remains effective for weeks with a single dose. In animal experiments, the compound proved to be a promising new candidate ...

Usage remains low for pill that can prevent HIV infection

January 8, 2018
From gritty neighborhoods in New York and Los Angeles to clinics in Kenya and Brazil, health workers are trying to popularize a pill that has proven highly effective in preventing HIV but which—in their view—remains woefully ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.